How does Libtayo (cemiplimab) affect the thyroid gland, and what monitoring and management steps are recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Libtayo and Thyroid Gland Effects

Libtayo (cemiplimab) causes immune-mediated thyroid dysfunction in approximately 6-25% of patients, typically manifesting as painless thyroiditis with initial thyrotoxicosis followed by permanent hypothyroidism requiring lifelong levothyroxine replacement. 1

Mechanism and Clinical Pattern

Cemiplimab, as a PD-1 checkpoint inhibitor, triggers immune-related thyroiditis through enhanced T-cell activity against thyroid tissue. The typical evolution follows a predictable biphasic pattern:

  • Thyrotoxicosis phase: Occurs at median 5-6 weeks after starting treatment, lasting approximately 6 weeks 2
  • Hypothyroidism phase: Develops in 84% of affected patients at median 10-17 weeks after ICI initiation 2
  • 67% of patients remain asymptomatic during thyrotoxicosis, making laboratory monitoring essential 2

Required Monitoring Protocol

Check TSH and free T4 at baseline and every 3-4 weeks during active treatment. 3, 1, 4 This frequent monitoring is critical because:

  • Thyroid dysfunction presents early (median 5.3 weeks) 2
  • Most patients are asymptomatic during the thyrotoxic phase 2
  • Delayed onset after treatment cessation is uncommon 4

For symptomatic patients, add T3 testing if FT4 elevations are minimal but symptoms are pronounced 3.

Management by Severity Grade

Grade 1 (Asymptomatic/Mild Thyrotoxicosis)

  • Continue cemiplimab without interruption 3
  • Beta-blocker (atenolol or propranolol) for symptomatic relief 3, 5
  • Recheck thyroid function every 2-3 weeks to catch transition to hypothyroidism 3
  • Do NOT use corticosteroids - thyroiditis is self-limited 3

Grade 2 (Moderate Symptoms)

  • Consider holding cemiplimab until symptoms return to baseline 3
  • Endocrine consultation recommended 3
  • Beta-blocker plus hydration/supportive care 3
  • If thyrotoxicosis persists >6 weeks, refer to endocrinology for additional workup 3

Grade 3-4 (Severe/Life-Threatening)

  • Hold cemiplimab until symptoms resolve 3
  • Mandatory endocrine consultation 3
  • Hospitalization for severe cases 3
  • Beta-blocker, hydration, consider steroids/SSKI/thionamides 3

Hypothyroidism Management

When TSH becomes elevated with low FT4 (the expected outcome in 84% of cases):

Initiate levothyroxine replacement immediately 3:

  • Age <70, no cardiac disease: Start full replacement at ~1.6 mcg/kg/day based on ideal body weight 3
  • Age >70 or cardiac disease/frailty: Start low at 25-50 mcg and titrate up 3
  • This hypothyroidism is permanent - patients remain on levothyroxine indefinitely 2

Critical Pitfall to Avoid

If low TSH with low FT4 is detected, this indicates central hypothyroidism from hypophysitis, NOT primary thyroid dysfunction. 3, 5 In this scenario:

  • Give hydrocortisone BEFORE initiating thyroid hormone 3, 5
  • Evaluate for hypophysitis (see pituitary workup) 5
  • Never start levothyroxine first in suspected central hypothyroidism - this can precipitate adrenal crisis 5

Risk Factors and Predictors

Patients at higher risk for severe hypothyroidism include those with:

  • Baseline positive thyroid antibodies (TPO/thyroglobulin) 2, 6
  • Elevated baseline TSH 6
  • Combination immunotherapy regimens (though cemiplimab is typically monotherapy) 4

Key Clinical Pearls

  • Elevated TSH during recovery from thyrotoxicosis: In asymptomatic patients with normal FT4, you may observe for 3-4 weeks before treating to assess for spontaneous recovery 3
  • Low TSH on levothyroxine therapy: Suggests overtreatment or thyroid function recovery - reduce or discontinue dose with close follow-up 3
  • Persistent thyrotoxicosis >6 weeks: Consider TSH receptor antibody testing to rule out Graves' disease (rare with cemiplimab but possible) 3, 5
  • Physical exam findings: Ophthalmopathy or thyroid bruit indicate Graves' disease requiring early endocrine referral 3

Treatment Continuation

Cemiplimab can and should be continued through thyroid dysfunction with appropriate hormone replacement. 3 Only hold for Grade 2-4 toxicity until symptoms resolve, then resume. The development of endocrinopathy does not require permanent discontinuation and may actually correlate with improved cancer outcomes 4.

References

2
Research

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.

Thyroid : official journal of the American Thyroid Association, 2018

Related Questions

What are the infection-related side effects of Libtayo (cemiplimab) and how should they be managed?
In a patient receiving durvalumab who presents with new‑onset thyrotoxicosis, can measuring serum thyroglobulin differentiate factitious hyperthyroidism from immune‑checkpoint‑inhibitor‑related thyroiditis?
How can I differentiate levothyroxine dose-related thyrotoxicosis from immune‑checkpoint inhibitor (ICI) induced thyrotoxicosis?
In a patient receiving checkpoint inhibitor immunotherapy (e.g., pembrolizumab, nivolumab, ipilimumab, atezolizumab) who develops thyroiditis with an initial thyrotoxic phase followed by hypothyroidism, what are the recommended baseline and serial thyroid function monitoring, first‑line treatment for the thyrotoxic and hypothyroid phases, criteria for holding or continuing immunotherapy, and when should endocrinology referral be considered?
In a patient on durvalumab who develops new‑onset thyrotoxicosis, what thyroglobulin (Tg) level is expected in immune‑related thyroiditis?
Can essential tremor present with an intention tremor?
Is there a short‑acting and long‑acting formulation of clonidine?
How can a primary psychiatric disorder be distinguished from dementia?
In a patient with a gout attack who has taken colchicine for two days and has an estimated glomerular filtration rate (eGFR) of 33 mL/min/1.73 m², can I prescribe additional colchicine?
What is the appropriate Augmentin (amoxicillin/clavulanate) dosage for an elderly patient with chronic obstructive pulmonary disease presenting with green sputum?
For an adult patient on methotrexate scheduled for elective surgery, how should the medication be managed perioperatively?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.